Our Clinical Sites and Trials

A5384: A Phase II, Randomized, Open-Label Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents with Tuberculous Meningitis: Improved Management with Antimicrobial AGents Isoniazid rifampiciN LinEzolid for TBM (IMAGINE-TBM)

Study Description A5384 is a trial for people who have or might have tuberculous meningitis (TBM). TBM is an infectious…

Active, Not Recruiting

See locations

ACTG A5362: A Phase IIc Trial of Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study

A5362 is a study for people with pulmonary tuberculosis (TB) without evidence of resistance to the TB drugs isoniazid (INH)…

Closed to accrual

See locations

A5341s: Intensive Reservoir Sampling, A5321 Substudy

A5341s: A5321 Sampling Substudy   Longitudinal Sampling Substudy of A5321 is collecting information from measures of different HIV reservoirs, including…

Open and enrolling

See locations

A5312: The Early Bactericidal Activity of High Dose or Standard Dose Isoniazid among adult Participants with Isoniazid-Resistant or Drug Sensitive Tuberculosis

This study is for participants who have pulmonary tuberculosis (TB), a bacterial infection in their lungs. Isoniazid (INH) is a…

Closed to accrual

About 23 days

See locations

A5415: A Limited-Center, Prospective, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living with HIV

The purpose of this study is to see if cenicriviroc mesylate (or CVC) can reduce inflammation of the arteries (the…

Open and enrolling

24 weeks

See locations

A5356: A Phase II, Prospective, Randomized, Multicenter Trial to Evaluate the Efficacy and Safety/Tolerability of Two Linezolid Dosing Strategies in Combination with a Short Course Regimen for the Treatment of Drug-Resistant Tuberculosis

Open and enrolling

See locations

A5394: Safety, Tolerability, and Impact of Oral TLR8 Agonist Selgantolimod on HBsAg

Open and enrolling

See locations

A5407: Placebo-controlled Phase 3 Outpatient Trial of Shionogi Agent for Treatment of Symptomatic SARS-CoV-2 Infection

Open and enrolling

See locations

A5377: Tri-specific Antibody

The first study of a broadly neutralizing antibody called SAR441236 in humans, will determine if an infusion is safe and…

Closed to accrual

Most participants will be followed on study for 24 weeks after their infusion. Participants who receive multiple infusions will be followed for a total of 72 weeks.

 

See locations

A5359: Long-Acting Antiretroviral Therapy in Non-adherent Persons Living with HIV (PLWH)

This four-step study compares Long-Acting (LA) Injectable Antiretroviral Therapy (ART) to standard of care (SOC) oral ART in previously non-adherent…

Open and enrolling

Steps 1-3 combined are a total of 128 weeks. Step 4 lasts 52 weeks.

See locations

A5354: Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses

Will evaluate whether starting antiretroviral drugs very early in HIV infection will limit the virus from getting into hidden areas…

Closed to accrual

The duration of the study is up to 72 weeks (a year and a half).

See locations

A5321: Decay of HIV-1 Reservoirs in Participants on Long-Term Antiretroviral Therapy: The ACTG HIV Reservoirs Cohort (AHRC) Study

Studies differences and changes over time in HIV reservoirs (groups of HIV infected cells that ’hide’ from anti-HIV medications).  

Open and enrolling

Participants will be expected to stay in the study for about 7 years.

 

See locations